Cargando…
Tropifexor‐Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in Rodents
Farnesoid X receptor (FXR) agonism is emerging as an important potential therapeutic mechanism of action for multiple chronic liver diseases. The bile acid‐derived FXR agonist obeticholic acid (OCA) has shown promise in a phase 2 study in patients with nonalcoholic steatohepatitis (NASH). Here, we r...
Autores principales: | Hernandez, Eloy D., Zheng, Lianxing, Kim, Young, Fang, Bin, Liu, Bo, Valdez, Reginald A., Dietrich, William F., Rucker, Paul V., Chianelli, Donatella, Schmeits, James, Bao, Dingjiu, Zoll, Jocelyn, Dubois, Claire, Federe, Glenn C., Chen, Lihao, Joseph, Sean B., Klickstein, Lloyd B., Walker, John, Molteni, Valentina, McNamara, Peter, Meeusen, Shelly, Tully, David C., Badman, Michael K., Xu, Jie, Laffitte, Bryan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6672390/ https://www.ncbi.nlm.nih.gov/pubmed/31388629 http://dx.doi.org/10.1002/hep4.1368 |
Ejemplares similares
-
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non–Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers
por: Badman, Michael K., et al.
Publicado: (2019) -
Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis
por: Schramm, Christoph, et al.
Publicado: (2022) -
Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial
por: Sanyal, Arun J., et al.
Publicado: (2023) -
Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study
por: Anstee, Quentin M., et al.
Publicado: (2023) -
Tropifexor, a selective non-acid farnesoid X receptor agonist, improved nonalcoholic steatohepatitis in a phase 2 trial, but several issues remain to be resolved
por: Yoneda, Masato, et al.
Publicado: (2023)